<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id>
<journal-title>Frontiers in Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Microbiol.</abbrev-journal-title>
<issn pub-type="epub">1664-302X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmicb.2017.01075</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Microbiology</subject>
<subj-group>
<subject>Correction</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Corrigendum: Cross-Talk between <italic>Staphylococcus aureus</italic> and Other Staphylococcal Species via the <italic>agr</italic> Quorum Sensing System</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Canovas</surname> <given-names>Jaime</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn003"><sup>&#x02020;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/363108/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Baldry</surname> <given-names>Mara</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/352551/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Bojer</surname> <given-names>Martin S.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/254181/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Andersen</surname> <given-names>Paal S.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/244329/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Grzeskowiak</surname> <given-names>Piotr K.</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Stegger</surname> <given-names>Marc</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/290760/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Damborg</surname> <given-names>Peter</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/284067/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Olsen</surname> <given-names>Christian A.</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/362918/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Ingmer</surname> <given-names>Hanne</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn001"><sup>&#x0002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/134757/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen</institution> <country>Frederiksberg, Denmark</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Microbiology and Infection Control, Statens Serum Institut</institution> <country>Copenhagen, Denmark</country></aff>
<aff id="aff3"><sup>3</sup><institution>Center for Biopharmaceuticals and Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen</institution> <country>Copenhagen, Denmark</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Susanne Fetzner, Universit&#x000E4;t M&#x000FC;nster, Germany</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Susanne Fetzner, Universit&#x000E4;t M&#x000FC;nster, Germany; Mattias Collin, Lund University, Sweden</p></fn>
<fn fn-type="corresp" id="fn001"><p>&#x0002A;Correspondence: Hanne Ingmer <email>hi&#x00040;sund.ku.dk</email></p></fn>
<fn fn-type="other" id="fn002"><p>This article was submitted to Systems Microbiology, a section of the journal Frontiers in Microbiology</p></fn>
<fn fn-type="present-address" id="fn003"><p>&#x02020;These authors have contributed equally to this work.</p></fn></author-notes>
<pub-date pub-type="epub">
<day>08</day>
<month>06</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>8</volume>
<elocation-id>1075</elocation-id>
<history>
<date date-type="received">
<day>10</day>
<month>04</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>29</day>
<month>05</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2017 Canovas, Baldry, Bojer, Andersen, Grzeskowiak, Stegger, Damborg, Olsen and Ingmer.</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>Canovas, Baldry, Bojer, Andersen, Grzeskowiak, Stegger, Damborg, Olsen and Ingmer</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<related-article id="RA1" related-article-type="corrected-article" journal-id="Front Microbiol" journal-id-type="nlm-ta" vol="7" page="1733" xlink:href="27877157" ext-link-type="pubmed">A corrigendum on <article-title>Cross-Talk between <italic>Staphylococcus aureus</italic> and Other Staphylococcal Species via the <italic>agr</italic> Quorum Sensing System</article-title> by Canovas, J., Baldry, M., Bojer, M. S., Andersen, P. S., Grzeskowiak, P. K., Stegger, M., et al. (2016). Front. Microbiol. 7:1733. doi: <object-id>10.3389/fmicb.2016.01733</object-id></related-article>
<kwd-group>
<kwd><italic>Staphylococcus aureus</italic></kwd>
<kwd><italic>Staphylococcus schleiferi</italic></kwd>
<kwd>quorum sensing</kwd>
<kwd><italic>agr</italic></kwd>
<kwd>quorum sensing inhibition</kwd>
<kwd>auto-inducing peptide</kwd>
<kwd>cross-talk</kwd>
<kwd>anti-virulence therapy</kwd>
</kwd-group>
<contract-num rid="cn001">1337-00129</contract-num>
<contract-num rid="cn001">1335-00772</contract-num>
<contract-sponsor id="cn001">Teknologi og Produktion, Det Frie Forskningsr&#x000E5;d<named-content content-type="fundref-id">10.13039/100008393</named-content></contract-sponsor>
<counts>
<fig-count count="1"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="4"/>
<page-count count="2"/>
<word-count count="1109"/>
</counts>
</article-meta>
</front>
<body>
<p>It has come to our attention that in Figure <xref ref-type="fig" rid="F1">4B</xref> of the original article, we stated that the <italic>S. schleferi</italic> autoinducing peptide has the sequence YPFCIAYF. This peptide was synthesized, tested and found to have inhibitory activity. However, the correct AIP sequence is YPFCIGYF. We have now synthesized this peptide with the protocol stated below, which differs from the one published, and have tested the correct peptide for activity. As demonstrated below, we find that the new peptide has strong agr inhibitory activity, as expected, and, therefore, the conclusions of the paper remain the same.</p>
<fig id="F1" position="float">
<label>Figure 4</label>
<caption><p><italic>S. schleiferi</italic> AIP interferes with <italic>S. aureus agr</italic>. <bold>(B)</bold> P3-blaZ expression recorded from <italic>S. aureus</italic> RN10829(P2-agrA:P3-blaZ)/pagrC-I (WT) when the inducing AIP-I containing supernatant (10%) is challenged for 45 min with different concentrations of synthetic <italic>S. schleiferi</italic> AIP at indicated concentrations. No induction and AIP-I containing supernatant alone were included as controls. Each bar represents the average of 3 biological replicates and the error bars represent the standard deviation.</p></caption>
<graphic xlink:href="fmicb-08-01075-g0001.tif"/>
</fig>
<sec sec-type="materials and methods" id="s2">
<title>Materials and methods</title>
<sec>
<title>Chemical synthesis of <italic>S. schleiferi</italic> AIP</title>
<p>The <italic>S. schleiferi</italic> AIP was synthesized applying a strategy based on the C-terminal peptide <italic>N</italic>-acyl-benzimidazolinone (Nbz) derivative (Blanco-Canosa and Dawson, <xref ref-type="bibr" rid="B1">2008</xref>), which was previously reported by Blackwell and coworkers (Tal-Gan et al., <xref ref-type="bibr" rid="B4">2016</xref>) for AIP syntheses. Briefly, the linear peptide (20.0 &#x003BC;mol) was synthesized on 3-(Fmoc-amino)-4-aminobenzoyl aminomethyl polystyrene resin (Dawson Dbz AM resin; 0.49 mmol/g, Merck) by automated Fmoc solid-phase peptide synthesis (SPPS) as described in the Materials and Methods of the manuscript. The peptide (5.00 &#x003BC;mol) was then cyclized by Nbz formation, TFA-mediated cleavage from the resin, and stirring in aqueous guanidinium chloride (6 M in 0.1 M phosphate buffer, pH &#x0003D; 6.8)&#x02013;MeCN (6:4) for 2 h at 50&#x000B0;C (Tal-Gan et al., <xref ref-type="bibr" rid="B4">2016</xref>). Cyclization was followed by purification as described in our manuscript to give the title compound as a white fluffy solid (1.9 mg, 28%).</p>
<p>Purity: &#x0003E;98% as determined by UPLC&#x02013;MS analysis at 230 nm.</p>
<p>MS: m/z calcd for C<sub>52</sub>H<sub>62</sub>N<sub>8</sub>O<sub>10</sub>S 991.4. ESI-MS found 991.4 [M&#x0002B;H<sup>&#x0002B;</sup>]. MALDI-TOF MS found 991.5 [M&#x0002B;H<sup>&#x0002B;</sup>].</p>
</sec>
<sec>
<title>&#x003B2;-lactamase assay and inhibitory concentration (IC<sub>50</sub>)</title>
<p>The method used is described by Nielsen et al. (<xref ref-type="bibr" rid="B3">2014</xref>). Briefly, the RN10829 (P2-agrA:P3-blaZ)/pagrC-I (WT) and RN10829(P2-agrA:P3-blaZ)/pagrC-I-R23H (AgrC const.) reporter strains were grown to an OD<sub>600</sub> of 0.4&#x02013;0.5 where a 1/10 volume of AIP-I containing supernatant (obtained from strain 8325-4) and 1/10 <italic>S. schleiferi</italic> supernatants were added to the reporter strain culture. In assays using heterologously expressed AIP<sub>Ss</sub> 1/20 volume of AIP-I containing supernatant was challenged with 1/5 volume supernatant from expression cultures. Samples obtained at 30 min time intervals after addition of test solutions were analyzed for &#x003B2;-lactamase activity by nitrocefin conversion. The IC<sub>50</sub> of the selected <italic>S. schleiferi</italic> supernatants was also tested using the &#x003B2;-lactamase assay, where a 1/10 volume (0.5 mL) of supernatant was added to the total volume of 5 mL of the reporter strain culture (RN10829-WT) representing the undiluted supernatant (100%). Then, 80, 60, 40, 20, 10, 5, 2.5 and 2% of the initial volume of the selected supernatant was added to obtain the IC<sub>50</sub> curve. Statistical analysis was performed using the Student&#x00027;s <italic>t</italic>-test (2-tailed).</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec>
<title><italic>S. schleiferi</italic> inhibition of <italic>S. aureus agr</italic> is AIP-mediated</title>
<p>To support that the <italic>S. schleiferi</italic> AIP that is responsible for inhibition of <italic>S. aureus</italic> RNAIII via AgrC agonist activity, we synthesized the <italic>S. schleiferi</italic> AIP with the sequence YPFCIGYF and tested the synthetic compound in the P3-<italic>blaZ</italic> reporter strain. Our results in this amended Figure <xref ref-type="fig" rid="F1">4B</xref> show that the <italic>S. schleiferi</italic> AIP is a potent inhibitor of <italic>S. aureus</italic> RNAIII expression and that it acts antagonistically on the reporter strain at low nanomolar concentrations.</p>
</sec>
<sec>
<title>Conflict of interest statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blanco-Canosa</surname> <given-names>J. B.</given-names></name> <name><surname>Dawson</surname> <given-names>P. E.</given-names></name></person-group> (<year>2008</year>). <article-title>An efficient Fmoc-SPPS approach for the generation of thioester peptide precursors for use in native chemical ligation</article-title>. <source>Angew. Chem. Int. Ed.</source> <volume>47</volume>, <fpage>6851</fpage>&#x02013;<lpage>6855</lpage>. <pub-id pub-id-type="doi">10.1002/anie.200705471</pub-id><pub-id pub-id-type="pmid">18651678</pub-id></citation></ref>
<ref id="B3">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname> <given-names>A.</given-names></name> <name><surname>M&#x000E5;nsson</surname> <given-names>M.</given-names></name> <name><surname>Bojer</surname> <given-names>M. S.</given-names></name> <name><surname>Gram</surname> <given-names>L.</given-names></name> <name><surname>Larsen</surname> <given-names>T. O.</given-names></name> <name><surname>Novick</surname> <given-names>R. P.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Solonamide B Inhibits Quorum Sensing and Reduces Staphylococcus aureus Mediated Killing of Human Neutrophils</article-title>. <source>PLoS ONE</source> <volume>9</volume>:<fpage>e84992</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0084992</pub-id><pub-id pub-id-type="pmid">24416329</pub-id></citation></ref>
<ref id="B4">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tal-Gan</surname> <given-names>Y.</given-names></name> <name><surname>Ivancic</surname> <given-names>M.</given-names></name> <name><surname>Cornilescub</surname> <given-names>G.</given-names></name> <name><surname>Blackwell</surname> <given-names>H. E.</given-names></name></person-group> (<year>2016</year>). <article-title>Characterization of structural elements in native autoinducing peptides and non-native analogues that permit the differential modulation of AgrC-type quorum sensing receptors in <italic>Staphylococcus aureus</italic></article-title>. <source>Org. Biomol. Chem.</source> <volume>14</volume>, <fpage>113</fpage>&#x02013;<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1039/c5ob01735a</pub-id><pub-id pub-id-type="pmid">26416476</pub-id></citation></ref>
</ref-list>
</back>
</article>
